The Breakthrough Medicine Program (BMP) is the Saudi Food and Drug Authority's accelerated pathway for medicines that treat serious or life-threatening conditions where existing options fall short. The SFDA issued its BMP guidance in October 2023, and the programme is now actively granting designations. It is voluntary, built on early dialogue between the developer and the SFDA, and it sits alongside the standard routes described in the SFDA Regulatory Framework for Drug Approval. This guide covers who qualifies, when to apply, and the obligations that follow a designation.
What the Breakthrough Medicine Program is for
The BMP exists to facilitate and accelerate both the development and the review of new medicines addressing unmet medical need in serious or life-threatening conditions. Rather than a separate registration route, it is a designation that changes how the SFDA engages with a product: earlier dialogue, closer guidance through development, and a compressed assessment once the file is submitted.
Participation is voluntary and the designation is requested by the applicant, not assigned by the SFDA. Because the programme is built on early engagement, the value is largely lost if a company applies only at the point of filing.
The four designation criteria — all four must be met
A product qualifies for Breakthrough Medicine Designation only if it satisfies every one of the following:
- It targets a serious, debilitating or life-threatening condition with an unmet medical need.
- It is likely to offer a major advantage over the methods currently in use.
- It demonstrates a positive benefit–risk balance.
- It is not yet registered with any stringent regulatory authority.
The fourth criterion is the one that disqualifies most applicants
The requirement that the product is not yet registered with any stringent regulatory authority rules out a large share of the portfolios companies bring to Saudi Arabia. If a medicine already holds an approval from the US FDA, EMA, MHRA, Health Canada, TGA, PMDA or Swissmedic, it is outside the BMP.
That is not a setback — it means the product belongs on a different and usually faster route. Products with a recognised reference approval are candidates for the verification or abridged assessment pathways, which rely on the reference authority's work rather than repeating it. Choosing between BMP and a reliance route is a strategic decision that should be made before any form is completed.
When to apply, and what the application contains
A designation request may be submitted from the end of phase 2 trials onwards, or at any point after. Applying earlier than that leaves too little evidence to argue the claim; applying much later forfeits the development-stage benefits the programme is designed to give.
The application consists of the Breakthrough Medicine Designation Form together with preliminary evidence — drawn from both non-clinical and clinical data — that the advantage claimed for the product is genuinely significant to patients and addresses their unmet need. The SFDA also expects a well-argued evaluation of how likely the product is to achieve that claim, based on the totality of information available at the time of the request.
After designation: a 30-working-day filing clock
Granting a designation starts a deadline that catches companies out. The applicant must submit the full medicine application file within 30 working days of the designation being granted, through the Saudi Drug Registration (SDR) system and in line with the SFDA's Guidance for Submission. For the mechanics of an SDR filing, see our guide to SFDA drug registration in Saudi Arabia.
The programme does allow for gaps. An applicant may request an exemption from one or more registration requirements where the document is genuinely unavailable at that stage — a Certificate of a Pharmaceutical Product (CPP), leaflet or artwork, for example. Exemptions are requested, not assumed, so each one needs to be identified and justified within the same 30-working-day window.
Review timeline and negotiating access in parallel
Once filed, the scientific assessment takes 60 working days. When the SFDA has sufficient information about the product it decides whether to grant a marketing authorisation.
The commercially significant feature of the programme is what a company may do during that window: the applicant can begin medication access negotiations with the relevant healthcare entities in parallel with the application review, rather than waiting for the authorisation. For a product treating a serious condition, running reimbursement and access discussions alongside assessment can compress the gap between approval and first patient treated by months.
The programme is active, not theoretical
The SFDA has granted Breakthrough Medicine Designations across several therapeutic areas, including the breast cancer therapy Inluriyo, and in March 2026 Bemlayo (orforglipron) for adults with obesity or overweight. In May 2026 a designation was granted for a therapy to prevent and reduce bleeding episodes in patients with haemophilia A.
The pattern is what the criteria predict: serious conditions, a defensible claim of major advantage, and products that had not yet been registered by a stringent authority at the time of the request.
How MRG supports a Breakthrough Medicine application
MRG holds SFDA Consultation Office license CO-2023-FO-0022 and manages BMP applications end to end: an honest eligibility assessment against all four criteria before anything is committed, preparation of the Designation Form and the preliminary evidence package, the argued likelihood-of-achievement evaluation, and management of the 30-working-day filing clock including any exemption requests.
Where a product turns out to be better served by the verification or abridged route, we will say so before the work is done rather than after. If you are planning a Saudi submission for a medicine treating a serious condition, talk to our consultants about which pathway actually fits, or explore our pharmaceutical regulatory services in Saudi Arabia.
Key Takeaway
The SFDA Breakthrough Medicine Program offers earlier dialogue, a 60-working-day scientific assessment and the ability to negotiate market access in parallel with review — but only for medicines meeting all four designation criteria, and notably only for products not yet registered by a stringent regulatory authority. Designation also starts a 30-working-day clock to file the full application, so the dossier work should be well advanced before the request is made.
Frequently Asked Questions
What are the SFDA Breakthrough Medicine Program criteria?
Four criteria, all of which must be met: the product targets a serious, debilitating or life-threatening condition with unmet medical need; it is likely to offer a major advantage over methods currently used; it shows a positive benefit–risk balance; and it is not yet registered with any stringent regulatory authority.
Can a medicine already approved by the FDA or EMA get SFDA breakthrough designation?
No. The fourth criterion excludes products already registered with a stringent regulatory authority. A medicine holding an FDA, EMA, MHRA, Health Canada, TGA, PMDA or Swissmedic approval is instead a candidate for the SFDA's verification or abridged assessment routes, which rely on that reference approval and are typically faster.
When can I apply for SFDA breakthrough designation?
From the end of phase 2 trials onwards, or at any time after. The request comprises the Breakthrough Medicine Designation Form plus preliminary non-clinical and clinical evidence supporting the claimed advantage, and a reasoned evaluation of how likely the product is to achieve that claim.
How long does the SFDA breakthrough pathway take?
The scientific assessment of the application takes 60 working days. Separately, once a designation is granted the applicant has 30 working days to submit the full medicine application file through the SDR system. Access negotiations with healthcare entities may run in parallel with the review.
